Concomitant Medication AssessmentsX Efficacy Assessments Body Imaging X XbSee Section 9.1 . Revised Protocol No.: 04 Date: 31-May-2019 36 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 2-5: Additional Treatment Fo llow-up Procedural Outline (CA021002) ProcedureSafety Follow-upaSurvival/Response Long-term Follow-up FU 1 30 days (±±7 days) FU 2 60 days (±7 days)FU 3 100 days (±7 days)Begins After Completion of Safety Follow-up Q12W ( ±2 weeks) Until 2 years After Last Dose of Study TreatmentNotes Brain ImagingFor participants with history of brain metastases, surveillance scans to be done per standard of care frequency, or sooner if clinically indicated.See Section 9.1 . Bone Scan As clinically indicated.